Tumor Proliferative Rate and Response to Chemotherapy
Authors: James O. Armitage
Journal: Annals of Internal Medicine (1992)

Editorials1 May 1992Tumor Proliferative Rate and Response to ChemotherapyJames O. Armitage, MDJames O. Armitage, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-9-771 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOne of the widely held ideas in oncology is that rapidly dividing tumors are sensitive to chemotherapy, whereas slowly growing tumors are resistant. This idea might have been fostered by the early success of chemotherapy in Burkitt lymphoma—perhaps the most rapidly proliferating human tumor. Also, the common "solid tumors" generally proliferate slowly and respond poorly to chemotherapy. However, another explanation for the same observations is that factors other than tumor growth rate determine sensitivity to chemotherapy but that some rapidly dividing tumors happen to be sensitive to chemotherapy. If the latter were true and because rapidly proliferating tumors might become...References1. Donhuijsen K. Mitoses in non-Hodgkin's lymphomas. Frequency and prognostic relevance. Pathol Res Pract. 1987;182:352-7. CrossrefMedlineGoogle Scholar2. AkermanBrandtJohnsonOlsson MLAH. Mitotic activity in non-Hodgkin's lymphoma. Relation to the Kiel classification and to prognosis. Br J Cancer. 1987;55:219-23. CrossrefMedlineGoogle Scholar3. BrandtJohnsonOlssonAkerman LAHM. Mitotic activity and survival in advanced non-Hodgkin's lymphoma of unfavourable histology. Eur J Cancer. 1990;26:227-30. CrossrefMedlineGoogle Scholar4. MacartneyCamplejohn JR. DNA flow cytometry of non-Hodgkin's lymphomas. Eur J Cancer. 1990;26:635-7. CrossrefMedlineGoogle Scholar5. DiamondNathwaniRappaport LBH. Flow cytometry in the diagnosis and classification of malignant lymphoma and leukemia. Cancer. 1982;50:1122-35. CrossrefMedlineGoogle Scholar6. WilsonMcNallyDischeSaundersRochersLewis GNSMCA. Measurement of cell kinetics in human tumors in vivo using bromodeoxyuridine incorporation and flow cytometry. Br J Cancer. 1988;58:423-31. CrossrefMedlineGoogle Scholar7. Del BinoSilvestriniCostaVeneroniGiardini GRASR. Morphological and clinical significance of cell kinetics in non-Hodgkin's lymphomas. Basic Appl Histochem. 1986;30:197-202. MedlineGoogle Scholar8. TurnerLayfieldBishopEpsteinParker RLPAJ. Flow cytometric measurements of proliferation-associated nuclear antigen p105 and DNA content in non-Hodgkin's lymphomas. Arch Pathol Lab Med. 1989;113:907-11. MedlineGoogle Scholar9. WeissStricklerMedeirosGerdesSteinWarnke LJLJHR. Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. Hum Pathol. 1987;18:1155-9. CrossrefMedlineGoogle Scholar10. BauerLincolnVera-RomanWallemarkChmielMadurski KSJCJM. Prognostic implications of proliferative activity and DNA aneuploidy in colonic adenocarcinomas. Lab Invest. 1987;57:329-35. MedlineGoogle Scholar11. KokalSheiboniTerzHorade WKJJ. Tumor DNA content in the prognosis of colorectal carcinoma. JAMA. 1986;225:3123-7. CrossrefGoogle Scholar12. VolmHahnMatternMullerVogt-MoykopfWeber MEJTIE. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res. 1988;48:2923-8. MedlineGoogle Scholar13. ClarkDresslerOwensPoundsOldakerMcGuire GLMGTW. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989;320:627-33. CrossrefMedlineGoogle Scholar14. SahinRoRoBlickel-NaggarOrdonez AJJMAN. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Cancer. 1991;68:549-57. CrossrefMedlineGoogle Scholar15. ParadisoTommasiMangiaLorussoSimoneDe Lena ASAVGM. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res. 1990;50:2958-62. MedlineGoogle Scholar16. BauerMerkelWinterMarderHauckWallemark KDJRWC. Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res. 1986;46:3173-8. MedlineGoogle Scholar17. CowanHarrisJonesCrowther RMMD. DNA content in high and intermediate grade non-Hodgkin's lymphoma—prognostic significance and clinicopathological correlations. Br J Cancer. 1989;60:904-10. CrossrefMedlineGoogle Scholar18. YoungHedleyRuggIland GDCH. The prognostic significance of proliferative activity in poor histology non-Hodgkin's lymphoma: a flow cytometry study using archival material. Eur J Cancer Clin Oncol. 1987;23:1497-504. CrossrefMedlineGoogle Scholar19. GroganLippmanSpierSlymenRybskiRangel TSCDJC. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood. 1988;71:1157-60. CrossrefMedlineGoogle Scholar20. O'BrienHolgateQuirkeStuartEllisElston CCPNIC. Correlation of morphology, immunophenotype, and flow cytometry with remission induction and survival in high grade non-Hodgkin's lymphoma. J Pathol. 1989;158:31-9. CrossrefMedlineGoogle Scholar21. ChristenssonLindemalmJohanssonMellstedtTribukaitBiberfeld BCBHBP. Flow cytometric DNA analysis: a prognostic tool in non-Hodgkin's lymphoma. Leuk Res. 1989;13:307-14. CrossrefMedlineGoogle Scholar22. WooldridgeGriersonWeisenburgerArmitageSangerCollins THDJWM. Association of DNA content and proliferative activity with clinical outcome in patients with diffuse mixed cell and large cell non-Hodgkin's lymphoma. Cancer Res. 1988;48:6608-13. MedlineGoogle Scholar23. GriersonWooldridgePurtiloJiersonBastWooldridge HTDJML. Low proliferative activity is associated with a favorable prognosis in peripheral T-cell lymphoma. Cancer Res. 1990;50:4845-8. MedlineGoogle Scholar24. RehnGlimeliusStrangSundstromTribukait SBPCB. Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma. Hematol Oncol. 1990;8:1-12. CrossrefMedlineGoogle Scholar25. Holtede Lange DaviesBeiskeStokkeMartonSmeland HCKTPE. Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer. 1989;44:975-80. CrossrefMedlineGoogle Scholar26. GriffinHowardQuirkeO'BrienChildBird NMPCJC. Prognostic indicators in centroblastic-centrocytic lymphoma. J Clin Pathol. 1988;41:866-70. CrossrefMedlineGoogle Scholar27. MacartneyCamplejohnAlderStonePowel JRJMG. Prognostic importance of DNA flow cytometry in non-Hodgkin's lymphomas. J Clin Pathol. 1986;39:542-6. CrossrefMedlineGoogle Scholar28. WilliamsonGrigorSmithHolgateO'BrienMorgan JIMCCD. Ploidy, proliferative activity, cluster differentiation antigen expression and clinical remission in high-grade non-Hodgkin's lymphoma. Histopathology. 1987;11:1043-54. CrossrefMedlineGoogle Scholar29. McLaughlinOsborneJohnstonJenningsButlerCabanillas PBDPJF. Nucleic acid flow cytometry in large cell lymphoma. Cancer Res. 1988;48:6614-9. MedlineGoogle Scholar30. MorganWilliamsonQuirkeClaydenSmithO'Brien DJPAMC. DNA content and prognosis of non-Hodgkin's lymphoma. Br J Cancer. 1986;54:643-9. CrossrefMedlineGoogle Scholar31. JalkanenJoensuuKlemi SHP. Prognostic value of lymphocyte homing receptor and S phase fraction in non-Hodgkin's lymphoma. Blood. 1990;75:1549-56. CrossrefMedlineGoogle Scholar32. SilvestriniCostaGiardiniBoracchiDel BinoMarubini RARPGE. Prognostic implications of cell kinetics, histopathology and pathologic stage in non-Hodgkin's lymphomas. Hematol Oncol. 1989;7:411-22. CrossrefMedlineGoogle Scholar33. JoensuuKlemiJalkanen HPS. Biologic progression in non-Hodgkin's lymphoma. Cancer. 1990;65:2564-71. CrossrefMedlineGoogle Scholar34. MillerGroganDaltonSpierScheperSalmon TTWCRS. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991;9:17-24. CrossrefMedlineGoogle Scholar35. SledgeEbleRothWuhrmanFinebergEinhorn GJBBNL. Relation of proliferative activity to survival in patients with advanced germ cell cancer. Cancer Res. 1988;48:3864-8. MedlineGoogle Scholar36. PriceHoganBlissHorwich PSJA. The growth rate of metastatic nonseminomatous germ cell testicular tumours measured by marker production doubling time—II. Prognostic significance in patients treated by chemotherapy. Eur J Cancer. 1990;26:453-7. CrossrefMedlineGoogle Scholar37. RazaPreislerDayYasinWhiteLykins AHRZMJ. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. Blood. 1990;76:2191-7. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClass III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilonePsychosocial stressors and mammary tumor growthTumor proliferative activity and response to first-line chemotherapy in advanced breast carcinomaHigh expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis 1 May 1992Volume 116, Issue 9Page: 771-773KeywordsChemotherapy Issue Published: 1 May 1992 PDF downloadLoading ...